Skip to main content
Contact Us
Subscribe
E-Edition
74°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
777.66
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jul 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Trump Threatens 200% Tariffs On Drug Imports, Says Big Pharma Will Get Some Time 'To Get Their Act Together'
July 08, 2025
Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation.
Via
Stocktwits
Topics
ETFs
Economy
Government
Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season
July 08, 2025
These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025
Via
MarketBeat
Topics
Economy
World Trade
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
July 08, 2025
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon."
Via
Investor's Business Daily
Topics
ETFs
Economy
Government
Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval
July 08, 2025
Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.
Via
Benzinga
WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformation
July 08, 2025
WeightWatchers completes reorganization, adds new leadership and unveils a women's health initiative targeting menopause care.
Via
Benzinga
LVM Capital Management Loads Up on NOC, Buys 6,237 Shares in Q2 2025
July 08, 2025
LVM Capital Management bought a $3.16 million stake in Northrop Grumman last quarter.
Via
The Motley Fool
Topics
Regulatory Compliance
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
July 08, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
2 S&P 500 Dividend Stocks That Could Climb 17% or More, According to Wall Street
July 08, 2025
Via
The Motley Fool
Topics
Stocks
3 Underrated Dividend Growth Stocks to Buy and Hold for Years
July 08, 2025
Via
The Motley Fool
Topics
World Trade
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
July 07, 2025
Via
Benzinga
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround
July 07, 2025
While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.
Via
Benzinga
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
July 07, 2025
Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns.
Via
Benzinga
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
July 07, 2025
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.
Via
Investor's Business Daily
3 No-Brainer Stocks to Buy in July
July 07, 2025
Via
The Motley Fool
Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert
July 07, 2025
Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access.
Via
Benzinga
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
July 07, 2025
Via
The Motley Fool
Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is...'
July 07, 2025
Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.
Via
Benzinga
Topics
Artificial Intelligence
2 Stocks to Buy on the Dip and Hold for 10 Years
July 06, 2025
Via
The Motley Fool
2 Dividend Growth Stocks to Buy and Hold Forever
July 06, 2025
Via
The Motley Fool
Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report
July 04, 2025
Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies .
Via
Benzinga
Topics
Government
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
July 04, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
The 9 Best Stocks to Buy Now in July (2025)
July 03, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
1 Unstoppable Vanguard Growth ETF to Buy With $400 in July
July 03, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
2 Cash-Producing Stocks Worth Investigating and 1 to Brush Off
July 03, 2025
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via
StockStory
Can Buying the Vanguard S&P 500 ETF Make You a Millionaire?
July 02, 2025
Via
The Motley Fool
Topics
ETFs
Economy
Stocks
2 Growth Stocks to Buy Hand Over Fist in July
July 02, 2025
These companies are poised to produce fireworks for your portfolio over the coming years.
Via
The Motley Fool
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
July 01, 2025
Via
The Motley Fool
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
July 01, 2025
Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.
Via
Benzinga
Got $200? 2 Biotech Stocks to Buy and Hold Forever
July 01, 2025
Via
The Motley Fool
Is the Vanguard S&P 500 Index Fund ETF a Buy Now?
July 01, 2025
Via
The Motley Fool
Topics
ETFs
Economy
Government
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.